Visual Outcomes Of A Novel Trifocal Intraocular Lens In Comparison To Its Monofocal Parent Intraocular Lens
Published 2024 - 42nd Congress of the ESCRS
Reference: FP25.12 | Type: Free paper | DOI: 10.82333/akvr-6v27
Authors: Francisco J. Castro* 1 , Javier Mendicute 2 , Martin Puzo 1 , Pavel Stodulka 3 , Marta Ibarz 4 , Javier Garcia Bella 5
1Hospital Nuestra Señora de Gracia,Zaragoza,Spain;GIMSO, Institute for Health Research Aragon,Zaragoza,Spain, 2Hospital Universitario Donostia,Donostia-Sebastian,Spain;Miranza Begitek,Donostia-Sebastian,Spain, 3Gemini Eye Clinic,Zlin,Czech Republic;3rd Faculty of Medicine, Charles University,Prague,Czech Republic, 4Grupo Oftalvist,Madrid,Spain, 5Hospital Clínico San Carlos,Madrid,Spain
Purpose
To compare the visual outcomes of the first hydrophobic acrylic refractive trifocal intraocular lens (IOL) (LuxLife, study group - Bausch + Lomb), with its aberration-free aspheric monofocal parent IOL (LuxGood, control group) in patients undergoing bilateral cataract surgery.
Setting
Seven clinical centers in Spain and Czech Republic.
Methods
A multicenter, prospective, non-randomized, open-label study that included cataract patients, aged 50 years or older with no ocular comorbidity, and maximum preoperative corneal astigmatism of 1.0 D. They were assigned (2:1) to bilateral implantation with LuxLife or LuxGood IOLs. End points included safety evaluation, manifest refraction spherical equivalent (MRSE), corrected distance visual acuity (CDVA), uncorrected and distance corrected intermediate visual acuity at 66 cm (UIVA and DCIVA), uncorrected and distance corrected near visual acuity at 40 cm (UNVA and DCNVA), and binocular defocus curve — all visual acuities expressed in logMAR scale. Patients were followed up for 4-6 months.
Results
170 patients were included: 115 in the study group (age: 68±6.9) and 55 in the control group (age: 73±6). The safety profile was similar between both IOLs. After 4-6 months, MRSE was -0.1±0.4 and 0±0.4. CDVA in the study group (0.05±0.1) was statistically non-inferior to the control group (-0.02±0.1). 59% vs 10% achieved monocular UIVA of 0.1 or better; 86% vs 21% achieved binocular UIVA of 0.1 or better; 56% vs 2% achieved monocular UNVA 0.1 or better; 90% vs 0% achieved binocular UNVA 0.1 or better. DCIVA was 0.1±0.1 and 0.3±0.1 (p<0.001), and DCNVA was 0.16±0.1 and 0.52±0.1 (p<0.001), respectively. Binocular defocus curve at a threshold of 0.2 logMAR of CDVA shows a depth of field of 3.25D and 1.5 D respectively.
Conclusions
This new refractive trifocal IOL (LuxLife) demonstrated superior intermediate and near visual acuity outcomes with good, non-inferior corrected distance visual acuity compared to its monofocal equivalent LuxGood. The LuxLife IOL provided a subjective accommodation amplitude of 3.25D with a similar safety profile to a monofocal.